All In Biotech

Investigational drug · Phase 2

BI 754111

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

5

Any phase or sponsor naming "BI 754111"

First trial start

2019

Mar 19, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "BI 754111", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Neoplasm Metastasis
  • Advanced Tumors
  • Metastatic Solid Tumors

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "BI 754111" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 4 on PubMed

Also in development for Neoplasm Metastasis

  • OlomorasibLY3537982Phase 36 trials

    Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis

  • TersolisibLY4064809, STX-478Phase 33 trials

    Eli Lilly · Breast Neoplasms, Neoplasm Metastasis, Breast Cancer

  • EzabenlimabBI 754091Phase 32 trials

    Boehringer Ingelheim · Advanced Cancer, Neoplasm Metastasis, Advanced Tumors

  • VepugratinibLY3866288Phase 32 trials

    Eli Lilly · Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3

  • BI 836880Phase 21 trial

    Boehringer Ingelheim · Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors

  • IPN60350Phase 21 trial

    Ipsen · Neoplasms, Neoplasm Metastasis, Neoplastic Processes

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.